FY2025 EPS Estimates for Curis Boosted by Cantor Fitzgerald

Curis, Inc. (NASDAQ:CRIS) – Equities researchers at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Curis in a report issued on Wednesday, April 30th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biotechnology company will post earnings of ($1.52) per share for the year, up from their previous forecast of ($2.34). The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

CRIS has been the topic of several other research reports. StockNews.com began coverage on Curis in a report on Wednesday. They set a “hold” rating on the stock. HC Wainwright dropped their price objective on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, March 31st.

Curis Stock Down 2.8 %

CRIS stock opened at $2.41 on Friday. Curis has a twelve month low of $1.02 and a twelve month high of $16.93. The company has a market cap of $20.46 million, a PE ratio of -0.31 and a beta of 3.51. The business’s 50-day simple moving average is $2.09 and its 200 day simple moving average is $3.18.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.11. The company had revenue of $2.70 million for the quarter, compared to analyst estimates of $2.04 million. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CRIS. Wealthquest Corp acquired a new stake in Curis during the 1st quarter valued at $1,542,000. M28 Capital Management LP increased its stake in shares of Curis by 23.5% in the fourth quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after buying an additional 99,108 shares in the last quarter. Bleichroeder LP raised its holdings in shares of Curis by 1,982.2% in the fourth quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock valued at $1,593,000 after buying an additional 495,540 shares during the last quarter. CM Management LLC raised its holdings in shares of Curis by 83.3% in the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock valued at $673,000 after buying an additional 100,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in Curis during the 4th quarter worth about $607,000. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.